Prognostic markers for CLL - how do they help determine who gets which treatment?
Exploiting signalling pathways involved in CLL to develop novel therapies
How far are we from a cure for CLL?
Update on ELOQUENT-2: Phase 3 trial of elotuzumab in relapsed/refractory multiple myeloma
Whole genome sequencing in CLL: challenges and benefits